Biogen (BIIB) stock
Last close $249.59 on 2026-11-20 (+1.00%) · Sector: Healthcare
Biogen is a healthcare company that discovers, develops and delivers medicines for people with serious illnesses, with a focus on neurological conditions. It makes money mainly by selling its approved therapies to patients, hospitals and health systems around the world.
Biogen closed at $249.59, about 4.4% below its 52-week high of $261. Over the past year the stock returned 41.2%, compared with 3.2% for the S&P 500, so it has beaten the broader market. Revenue is growing slowly at 2.4%, and profit has been uneven in recent quarters. Two small insider sales were reported in 2026, and the stock rose the day after 4 of its 7 recent earnings reports.
Key numbers
- Market cap: $36.9B
- Revenue (last 12 months): $10.30B
- Revenue growth: +2.4%
- Gross margin: 74.1%
- P/E: 107.6
- P/S: 3.6
- Debt to equity: 0.39
- Current ratio: 1.94
Quality score
Overall 31/100 · growth 32 · profitability None · financial health 60 · value 0
Performance and risk
1-year return +41.2% vs S&P 500 +3.1% · volatility 34.2% (S&P 500 14.2%) · largest drop -14.3% · beta 0.35
Stock move the day after earnings
- 2026-01-14: -0.4%
- 2026-02-06: +8.5%
- 2026-04-06: -2.8%
- 2026-04-29: +6.0%
- 2026-07-01: +3.0%
- 2026-07-29: +1.8%
- 2026-10-28: -3.4%
Insider trades (12 months)
Bought $0.0M · sold $0.9M
BIIB stock research · BIIB options calculator · Stocks to buy, hold or sell today
StrikeWright provides AI signals only, not financial advice.